These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 17624607)

  • 1. Vitamin D intake may be a predictor of response to aromatase inhibitors in postmenopausal women with hormone receptor positive breast cancer.
    Dizdar O; Bulut N; Altundag K
    Breast Cancer Res Treat; 2008 May; 109(2):403. PubMed ID: 17624607
    [No Abstract]   [Full Text] [Related]  

  • 2. Vitamin D supplementation and response to aromatase inhibitors in postmenopausal women with hormone-receptor positive breast cancer.
    Dizdar O; Bulut N; Altundag K
    Breast; 2008 Apr; 17(2):120. PubMed ID: 18037293
    [No Abstract]   [Full Text] [Related]  

  • 3. Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer.
    Dixon JM
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):453-63. PubMed ID: 18366292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: evidence based review.
    Poole R; Paridaens R
    Curr Opin Oncol; 2007 Nov; 19(6):564-72. PubMed ID: 17906453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis of pre-operative aromatase inhibitor versus tamoxifen in postmenopausal woman with hormone receptor-positive breast cancer.
    Seo JH; Kim YH; Kim JS
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):261-6. PubMed ID: 18365197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Adjuvant endocrine therapy for postmenopausal women].
    Watanabe G; Ishida T; Ohuchi N
    Nihon Rinsho; 2012 Sep; 70 Suppl 7():636-40. PubMed ID: 23350476
    [No Abstract]   [Full Text] [Related]  

  • 7. Adjuvant endocrine therapy for perimenopausal women with early breast cancer.
    Ortmann O; Cufer T; Dixon JM; Maass N; Marchetti P; Pagani O; Pronzato P; Semiglazov V; Spano JP; Vrdoljak E; Wildiers H
    Breast; 2009 Feb; 18(1):2-7. PubMed ID: 19036588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anti-aromatase acting drugs].
    Diedrich K
    Krankenpfl J; 2005; 43(4-6):150-1. PubMed ID: 16171094
    [No Abstract]   [Full Text] [Related]  

  • 9. Addressing the future: combination with targeted therapies, adjuvant setting and beyond.
    Goss PE
    Anticancer Drugs; 2008 Mar; 19 Suppl 2():S3-5. PubMed ID: 18337641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant endocrine therapy in post menopausal women: pharmacological evaluation using decision analysis approach in a Japanese hospital setting.
    Miyazaki Y; Arakawa I; Inoue T
    Gan To Kagaku Ryoho; 2009 Aug; 36(8):1299-309. PubMed ID: 19692769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R
    Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy and safety of high-dose toremifene for hormone-responsive advanced or metastatic breast cancer patients with failed prior treatment by aromatase inhibitors].
    Ohtake T; Yasuda M; Watanabe K; Ito T; Ito J; Miyamoto K; Yoshida S; Abe N; Ishigame T; Ishii M; Kimijima I; Takenoshita S
    Gan To Kagaku Ryoho; 2009 Sep; 36(9):1459-63. PubMed ID: 19755813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent topics in endocrine therapy for hormone-dependent breast cancer: basic research and clinical applications.
    Kimijima I
    Breast Cancer; 2008; 15(4):253-5. PubMed ID: 18953680
    [No Abstract]   [Full Text] [Related]  

  • 14. Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole.
    Miller WR; Larionov A; Renshaw L; Anderson TJ; Walker JR; Krause A; Sing T; Evans DB; Dixon JM
    J Clin Oncol; 2009 Mar; 27(9):1382-7. PubMed ID: 19224856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in adjuvant endocrine therapy for postmenopausal women.
    Lin NU; Winer EP
    J Clin Oncol; 2008 Feb; 26(5):798-805. PubMed ID: 18258989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression of endocrine therapies for breast cancer: where are we headed?
    Arnedos M; Smith I
    Expert Rev Anticancer Ther; 2007 Nov; 7(11):1651-64. PubMed ID: 18020931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
    Wardley AM
    Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Extended adjuvant hormone therapy (in breast cancer): Why? To whom? What? How long?].
    Kahán Z
    Magy Onkol; 2008 Jun; 52(2):225-6. PubMed ID: 18640899
    [No Abstract]   [Full Text] [Related]  

  • 19. [Aromatase inhibitors for metastasing breast cancer in postmenopausal women. A survey of a Cochrane review].
    Aziz M; Skougaard K; Kamby C; Nielsen DL
    Ugeskr Laeger; 2008 Jun; 170(25):2248-52. PubMed ID: 18565316
    [No Abstract]   [Full Text] [Related]  

  • 20. Aromatase inhibitors in breast cancer.
    Hiscox S; Davies EL; Barrett-Lee P
    Maturitas; 2009 Aug; 63(4):275-9. PubMed ID: 19577386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.